Reverse-phase HPLC raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-03-06. Anything still debated is marked as such rather than presented as settled.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Lyophilized peptide is normally kept at minus twenty degrees Celsius or colder, away from light and moisture. Powder held under those conditions is widely treated as stable for long periods, although published stability studies for this exact sequence are sparse and often come from suppliers rather than independent laboratories. Once dissolved, solutions are generally handled cold and used within a short window, because peptide bonds can hydrolyze over time. Repeated freeze-thaw cycles are usually avoided to limit losses, and exact shelf-life figures depend on the buffer and the concentration involved.
Purity is ordinarily reported as a percentage from reverse-phase high-performance liquid chromatography, where the area of the main peak is compared with the total peak area. Identity is confirmed by mass spectrometry, since the measured mass can be checked against the value calculated from the sequence. Some certificates also include amino acid analysis or sequence confirmation by tandem mass spectrometry. A single purity number does not describe the profile of related impurities, so the underlying chromatogram and spectrum usually carry more information than the headline figure.
Most published studies examine BPC-157 in animal models rather than in humans. Common subjects include rats and mice, and researchers often use models of tissue injury, surgery, or induced inflammation. Reported endpoints include healing rates, blood vessel formation, and markers of tissue repair. These designs provide controlled comparisons, but findings in animals do not automatically transfer to people. Human clinical data remain limited and are frequently described as preliminary.
Doses in the literature are usually expressed in micrograms or nanograms per kilogram of body weight. Investigators have administered the peptide by several routes, including injection and oral delivery, depending on the question asked. Route and dose vary widely across studies, which complicates direct comparison of results. Many papers report effects at low doses, but the absence of a standardized protocol limits generalization. Reporting practice differs between research groups.
The Saviz served in this capacity until it was damaged in an Israeli limpet mine attack in April 2021, when it was replaced by the MV Behshad. The Behshad, like the Saviz, is based on a cargo ship. Meanwhile, in Yemen, the Houthis, presumably with the assistance of Iranian engineers, converted a number of 10-meter-long patrol craft donated by the UAE to the Yemeni Coast Guard in the early 2010s into WBIEDs (water born improvised explosive devices). In 2017, one of these was used to attack the Saudi frigate Al Madinah. In the years since, three more WBIED designs have been built: the Tawfan-1, Tawfan-2, and Tawfan-3. 15 different types of naval mines were also produced. These are being increasingly deployed in the Red Sea, but have yet to be successful against naval vessels. The delivery of 120 km-ranged Noor and 200 km-ranged Qader AShMs, 300 km-ranged Khalij Fars ASBMs, and Fajr-4CL and "Al-Bahr Al-Ahmar" anti-ship rockets by Iran, which were unveiled during a 2022 Houthi parade, was arguably the most significant escalation in support. They combine long range, low cost, and high mobility with various types of guidance to create a weapon well-suited to the Houthi Navy. Though the Houthis' ASBM arsenal has yet to be tested, the Houthi Navy has had notable success with AShMs. On 1 October 2016, it was able to hit the UAE Navy's HSV-2 Swift hybrid catamaran with a single C-801/C-802 AShM fired from a shore battery. Although the ship managed to stay afloat, the damage was so severe that it had to be decommissioned.
== Society and culture == In the United States the FDA requires tablets of the medication to be sold by prescription. Potassium permanganate, however, does not have FDA approved uses and therefore non medical grade potassium permanganate is sometimes used for medical use. It is available under a number of brand names including Permasol, Koi Med Tricho-Ex, and Kalii permanganas RFF. It is occasionally called "Condy's crystals".
=== Black Consciousness and empowerment === Biko rejected the apartheid government's division of South Africa's population into "whites" and "non-whites", a distinction that was marked on signs and buildings throughout the country. Building on Fanon's work, Biko regarded "non-white" as a negative category, defining people in terms of an absence of whiteness. In response, Biko replaced "non-white" with the category "black", which he regarded as being neither derivative nor negative. He defined blackness as a "mental attitude" rather than a "matter of pigmentation", referring to "blacks" as "those who are by law or tradition politically, economically and socially discriminated against as a group in the South African society" and who identify "themselves as a unit in the struggle towards the realization of their aspirations". In this way, he and the Black Consciousness Movement used "black" in reference not only to Bantu-speaking Africans but also to Coloureds and Indians, who together made up almost 90% of South Africa's population in the 1970s. Biko was not a Marxist and believed that it was oppression based on race, rather than class, which would be the main political motivation for change in South Africa. He argued that those on the "white left" often promoted a class-based analysis as a "defence mechanism... primarily because they want to detach us from anything relating to race. In case it has a rebound effect on them because they are white".
Sources: en.wikipedia.org
=== Domestic politics === On the outbreak of war, Huggins invited the leader of the opposition Labour Party, Harry Davies, to join a coalition government. Davies accepted without consulting his party caucus, much to the indignation of many of his contemporaries; Labour promptly split. The two Labour factions reconciled in 1943 and briefly threatened Huggins's premiership until a heated dispute over whether Labour should become multiracial led to the party's disintegration in 1944.
== Further reading == J. Buikstra, 1977. "Biocultural dimensions of archaeological study: a regional perspective". In:Biocultural adaptation in prehistoric America, pp. 67–84. University of Georgia Press. J. Buikstra and L. Beck, eds., 2006. "Bioarchaeology: the Contextual Study of Human Remains." Elsevier. M. Katzenberg and S. Saunders, eds., 2000. Biological anthropology of the human skeleton. Wiley. K. Killgrove, 2014. Bioarchaeology Archived 2019-06-26 at the Wayback Machine. In: Oxford Annotated Bibliographies Online. Oxford. C.S. Larsen, 1997. Bioarchaeology: interpreting behavior from the human skeleton. Cambridge University Press. Law, Matt (2019). "Beyond Extractive Practice: Bioarchaeology, Geoarchaeology and Human Palaeoecology for the People". Internet Archaeology (53). doi:10.11141/ia.53.6. S. Mays, 1998. The archaeology of human bones. Routledge. Samuel J. Redman, 2016. Bone Rooms: From Scientific Racism to Human Prehistory in Museums. Harvard University Press. M. Parker Pearson, 2001. The archaeology of death and burial. Texas A&M University Press. D. Ubelaker, 1989. Human skeletal remains: excavation, analysis, interpretation. Taraxacum. T. White, 1991. Human osteology. Academic Press.
RNA interference (RNAi) is a biological process in which RNA molecules are involved in sequence-specific suppression of gene expression by double-stranded RNA, through translational or transcriptional repression. Historically, RNAi was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. The detailed study of each of these seemingly different processes elucidated that the identity of these phenomena were all actually RNAi. Andrew Fire and Craig Mello shared the 2006 Nobel Prize in Physiology or Medicine for their work on RNAi in the nematode worm Caenorhabditis elegans, which they published in 1998. Since the discovery of RNAi and its regulatory potentials, it has become evident that RNAi has immense potential in suppression of desired genes. RNAi is now known as precise, efficient, stable and better than antisense therapy for gene suppression. Antisense RNA produced intracellularly by an expression vector may be developed and find utility as novel therapeutic agents. Two types of small ribonucleic acid (RNA) molecules, microRNA (miRNA) and small interfering RNA (siRNA), are central to components to the RNAi pathway. Once mRNA is degraded, post-transcriptional silencing occurs as protein translation is prevented. Transcription can be inhibited via the pre-transcriptional silencing mechanism of RNAi, through which an enzyme complex catalyzes DNA methylation at genomic positions complementary to complexed siRNA or miRNA.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
It does not occur in the form that is supplied commercially. Its sequence matches a fragment of a larger gastric protein, and the research material is produced synthetically in a laboratory. The fragment described in the early literature is generally the same synthetic pentadecapeptide.